BKM120 in combination with LH-RH agonists (suprefact) and bicalutamide
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non Castrate Metastatic Prostate Cancer
Conditions
Non Castrate Metastatic Prostate Cancer
Trial Timeline
Oct 1, 2014 → Nov 1, 2017
NCT ID
NCT02487823About BKM120 in combination with LH-RH agonists (suprefact) and bicalutamide
BKM120 in combination with LH-RH agonists (suprefact) and bicalutamide is a phase 1 stage product being developed by Novartis for Non Castrate Metastatic Prostate Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT02487823. Target conditions include Non Castrate Metastatic Prostate Cancer.
What happened to similar drugs?
1 of 4 similar drugs in Non Castrate Metastatic Prostate Cancer were approved
Approved (1) Terminated (1) Active (2)
❌custirsen sodium + isotonic, 0.9% sodium chloride + docetaxel + cabazitaxel + prednisoneAchieve Life SciencesPhase 3
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02487823 | Phase 1 | Terminated |
Competing Products
20 competing products in Non Castrate Metastatic Prostate Cancer